Actively Recruiting
Cohort Observing Mechanisms, Progression and Sequelae of Valvular Heart Disease
Led by Second Affiliated Hospital, School of Medicine, Zhejiang University · Updated on 2025-12-05
10000
Participants Needed
15
Research Sites
260 weeks
Total Duration
On this page
Sponsors
S
Second Affiliated Hospital, School of Medicine, Zhejiang University
Lead Sponsor
A
Army Medical Center of PLA
Collaborating Sponsor
AI-Summary
What this Trial Is About
The objective of this study is to evaluate and predict the progression of moderate cardiac valve stenosis and regurgitation using clinical, biological, echocardiographic, computed tomography (CT), and magnetic resonance imaging (MRI) data. Additionally, the study aims to analyze the potential impact of device-based interventions, pharmacological therapy, and lifestyle modifications on disease progression.
CONDITIONS
Official Title
Cohort Observing Mechanisms, Progression and Sequelae of Valvular Heart Disease
Who Can Participate
Eligibility Criteria
You may qualify if you...
- At least 18 years old
- Willing and able to provide informed consent to participate
- Diagnosed with heart valve disease by echocardiography meeting at least one of the following:
- Grade II or higher Aortic valve regurgitation with specific echocardiographic criteria
- Moderate or higher aortic valve stenosis with specific echocardiographic criteria
- Grade II or higher mitral valve regurgitation with specific echocardiographic criteria
- Moderate or higher valve stenosis with specific echocardiographic criteria
- Grade II or higher tricuspid valve regurgitation with specific echocardiographic criteria
- Significant tricuspid valve stenosis with specific echocardiographic criteria
- Grade II or higher pulmonary valve regurgitation with specific echocardiographic criteria
- Moderate or higher pulmonary valve stenosis with specific echocardiographic criteria
You will not qualify if you...
- Unwilling to accept registration and follow-up
- Unable to cooperate with information collection and follow-up due to mental illness or other conditions
- Life expectancy less than 12 months due to non-cardiac diseases such as cancer, liver disease, kidney disease, or end-stage lung disease
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 15 locations
1
Fujian Provincial Hospital, Affiliated to Fuzhou University
Fuzhou, Fujian, China
Actively Recruiting
2
Renmin Hospital of Wuhan University
Wuhan, Hubei, China, 430060
Actively Recruiting
3
Xiangya Hospital of Central South University
Changsha, Hunan, China, 410008
Actively Recruiting
4
Second Xiangya Hospital of Central South University
Changsha, Hunan, China
Actively Recruiting
5
The General Hospital of Northern Theater Command
Shenyang, Liaoning, China, 110031
Actively Recruiting
6
The First Affiliated Hospital of Air Force Medicial University
Xi'an, Shaanxi, China, 710032
Actively Recruiting
7
Affiliated Hospital of Qingdao University
Qingdao, Shandong, China, 266000
Actively Recruiting
8
Huaxi Hospital
Chengdu, Sichuan, China
Actively Recruiting
9
People's Hospital of Xinjiang Uygur Autonomous Region
Ürümqi, Xinjiang, China, 830000
Actively Recruiting
10
Fuwai Yunnan Cardiovascular Hospital
Kunming, Yunnan, China, 650032
Actively Recruiting
11
Second Affiliated Hospital of Zhejiang University, School of Medicine
Hangzhou, Zhejiang, China, 310000
Actively Recruiting
12
Chinese Academy of Medical Sciences, Fuwai Hospital
Beijing, China
Actively Recruiting
13
Navy General Hospital, Beijing
Beijing, China
Actively Recruiting
14
Army Medical Center of PLA
Chongqing, China, 400010
Actively Recruiting
15
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
Shanghai, China, 200080
Actively Recruiting
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
0
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here